Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of atorvastatin or medical salt thereof in preparation of medicines for treating uterine fibroid

A technology of atorvastatin and uterine fibroids, which is applied in the field of medicine, can solve the problems of unestablished effects of statins on the risk of renal cell carcinoma, reduce the risk of renal cell carcinoma, etc., achieve the purpose of inhibiting the growth of uterine fibroids and promoting apoptosis. death effect

Inactive Publication Date: 2018-05-29
THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Another study did not establish an effect of statins on the risk of renal cell carcinoma, subgroup analysis showed that the use of statins in women and those without a history of hypertension may reduce the risk of renal cell carcinoma
[0010] However, there is no prior art disclosing the use of atorvastatin for the treatment of uterine fibroids

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of atorvastatin or medical salt thereof in preparation of medicines for treating uterine fibroid
  • Application of atorvastatin or medical salt thereof in preparation of medicines for treating uterine fibroid
  • Application of atorvastatin or medical salt thereof in preparation of medicines for treating uterine fibroid

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Embodiment 1, the clinical study of atorvastatin inhibiting the growth of uterine fibroids

[0032] To explore the effect of atorvastatin on the development and changes of uterine fibroids. 120 patients with uterine fibroids. Patients with uterine fibroids complicated with hyperlipidemia were selected as the medication group, and patients with uterine fibroids complicated with hyperlipidemia who did not take statins were selected as the control group. The volume changes of uterine fibroids were observed and compared between the two groups within 2 years. The volume of fibroids in the control group showed a tendency to increase after 1 year and 2 years, and there was a significant difference compared with the original volume of fibroids (P0.05). The volume changes of myomas in the control group at 1 year and 2 years were significantly greater than those in the medication group (Pfigure 1 ).

Embodiment 2

[0033] Embodiment 2, the in vitro study of atorvastatin inhibiting the growth of uterine leiomyoma cells

[0034] Cell culture and processing: The uterine fibroid tissue was cut out aseptically during the operation, washed with PBS buffer, cut into pieces and placed in 0.2% type II collagenase, digested at 37°C for 4-6 hours, centrifuged at 1000rpm for 3 minutes, and discarded. For the supernatant, add 5 mL of preheated complete medium to neutralize, then discard the supernatant again. Add the culture medium and blow it into a cell suspension. The primary uterine leiomyoma cells are cultured in a medium containing 10% fetal bovine serum at 37°C and 5% CO 2 Cultivate in an incubator, replace the medium in time according to the growth rate of the cells, digest and disperse the cells with 0.25% trypsin solution, and carry out passage or inoculation culture. During drug treatment, atorvastatin was prepared into a 40 mM original solution with dimethyl sulfoxide (DMSO), and then ...

Embodiment 3

[0040] Example 3. Research on the mechanism of atorvastatin inhibiting the growth of uterine leiomyoma cells

[0041] 3.1 Cell culture: Primary uterine fibroid cells and immortalized uterine fibroid cells were respectively cultured in complete medium containing 10% fetal bovine serum at 37°C and 5% CO 2 Cultivate in an incubator, replace the medium in time according to the growth rate of the cells, digest and disperse the cells with trypsin solution, and carry out passage or inoculation culture. For drug treatment, atorvastatin with a final concentration of 1-40 μM was added to the culture medium, cultured in an incubator, and then the following tests were performed respectively.

[0042] 3.2 Western blotting

[0043] 3.2.1 Extraction of cell protein

[0044] 1) Remove the culture medium from the adherent cells, wash gently with pre-cooled PBS twice, and discard the PBS;

[0045] 2) Add 100 μL of the pre-prepared cell lysate to ensure that all cells are infiltrated with t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of atorvastatin in preparation of medicines for treating uterine fibroid. The medicine is used for inhibiting the growth of immortalized uterine fibroid cells and primary uterine fibroid cells, including inhibiting of cell proliferation, and promoting of cell apoptosis. The atorvastatin is used for inhibiting the growth of uterine fibroid cells by down-regulating the expression of proliferation protein PCNA and anti-apoptosis protein Bc1-2, up-regulating the expression of apoptosis protein cleaved-caspase 3 and Bim, inhibiting a signal channel of MAPK (mitogen-activated protein kinase), down-regulating the activity of p-ERK1 / 2 (phospho-extracellular regulated protein kinases 1 / 2), inhibiting the activity of HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A), and inhibiting the mevalonate pathway. The application of the blood fat-decreasing medicine, namely the atorvastatin, in the treatment of the uterine fibroid is proofed by the experiment, and the effect of inhibiting the growth of the uterine fibroid is obtained.

Description

technical field [0001] The invention belongs to the field of medicine and relates to a new application of atorvastatin, in particular to the application of atorvastatin in the preparation of medicaments for treating uterine fibroids. Background technique [0002] Uterine fibroids are the most common benign tumors in women of childbearing age, mainly formed by the proliferation of uterine smooth muscle cells. According to reports, the prevalence of uterine fibroids in women aged 50 is as high as 70%-80%. With the increase of age, the volume of fibroids gradually increases, and some patients will have more serious clinical symptoms, such as increased menstrual flow, prolonged menstrual periods, bladder and rectal compression symptoms caused by huge masses, pelvic pain, infertility, miscarriage, etc., severe affect women's reproductive health. At present, according to the size, location, symptoms, age and whether there is a need for fertility, the treatment methods of uterine...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/40A61P35/00A61P15/00
CPCA61K31/40
Inventor 朱雪琼盛波沈昭君诸海燕张琼
Owner THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com